Showing 4711-4720 of 7516 results for "".
- New Jersey Passes Law Prohibiting Indoor Tanning for Those Under 17https://practicaldermatology.com/news/20130402-new_jersey_passes_law_prohibiting_indoor_tanning_for_those_under_17/2459575/The state of New Jersey recently passed a law that bans minors under the age of 17 years old from using indoor tanning devices. The law passed both the New Jersey House and Senate in February and was signed into law by Gov. Christopher Christie on April 1, 2013. Dirk M. Elston, MD, FAAD, President o
- Site Aims to Steer Patients to Physicians' Informationhttps://practicaldermatology.com/news/20130401-site_aims_to_steer_patients_to_physicians_information/2459577/Giving patients the proper information has always been important for physicians, and accessible handout literature has been the easiest ways to keep bad information out of their hands. But to keep pace with how quickly patients get their information, Vivacare allows physicians to enroll online free
- New Survey Finds Social Media is a Major Influence on Elective Surgeryhttps://practicaldermatology.com/news/20130327-new_survey_finds_social_media_is_a_major_influence_on_elective_surgery/2459578/Social media is leading consumers to have a more self-critical eye, according to a new survey by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS). The annual poll of the organization's board-certified facial plastic surgeons found a 31 percent increase in requests for surge
- Skin Cancer Foundation Inducts Dr. Amy Forman Taub into its Amonette Circlehttps://practicaldermatology.com/news/20130327-skin_cancer_foundation_inducts_amy_forman_taub_md_into_its_amonette_circle/2459579/Amy Forman Taub, MD, was recently inducted into the Skin Cancer Foundation's Amonette Circle at the American Academy of Dermatology Annual Meeting in Miami, FL. Amonette Circle is a lifetime membership comprised of physicians who make an outstanding commitment to The Skin Cancer Foundation's mission
- Investigational Melanoma Agent Meets Endpoint in Phase 3 Trialhttps://practicaldermatology.com/news/20130320-investigational_melanoma_agent_meets_endpoint_in_phase_3_trial/2459582/New Phase 3 trial data found that Amgen's investigational melanoma agent talimogene laherparepvec met its primary endpoint of durable response rate for the treatment of unresected stage IIIB, IIIC, or IV melanoma. Researchers observed a statistically significant difference of 16 percent in DRR in pa
- Survey: Scars and Stretch Marks Significantly Impact Women's Confidencehttps://practicaldermatology.com/news/20130318-survey_scarsstretch_marks_have_significant_negative_impact_womens_confidence/2459586/A new survey reveals that men and women have complex and often differing feelings about how their skin Imperfections impact their appearance and confidence. In the Mederma® Wear Your Skin Proudly™ survey, 34 percent of women reported that the appearance of scar(s) and/or stretch marks would make the
- NeoStrata Introduces Line Lift Duohttps://practicaldermatology.com/news/20130314-neostrata_introduces_line_lift_duo/2459589/NeoStrata Company, Inc. launched the SKIN ACTIVE Line Lift featuring Aminofil™, a novel tyrosine amino acid derivative (N-Acetyl Tyrosinamide) that delivers a rapid volumizing effect in the deep skin matrix to visibly reduce deep facial lines and wrinkles. Applied together twice daily, the SKIN ACTI
- Investigational Injectable Found Safe, Effective for Submental Fathttps://practicaldermatology.com/news/20130311-investigational_injectable_found_safe_effective_for_submental_fat/2459596/An investigational injectable drug for the reduction of submental fat called ATX-101 from Kythera Biopharmaceuticals was found both safe and effective in new data presented at the AAD Meeting in Miami. In the open-label Phase IIIb study, interim results three months after the last ATX-101 treatment
- Apremilast Phase III Results Show Efficacy Over Time for Psoriasishttps://practicaldermatology.com/news/20130311-apremilast_phase_iii_results_show_efficacy_over_time_for_psoriasis/2459597/Results from a new Phase III study presented at the AAD Meeting in Miami demonstrate the efficacy of the oral molecule apremilast (Celgene) in psoriasis patients. The ESTEEM 1 study evaluated efficacy and safety in a range of patients, approximately one-third of which was systemic and/or phototherap
- Omalizumab Shown to Significantly Improve Chronic Idiopathic Urticaria Symptomshttps://practicaldermatology.com/news/20130227-omalizumab_shown_to_significantly_improve_chronic_idiopathic_urticaria_symptoms/2459605/Results from the recent ASTERIA II trial showed that the biologic agent omalizumab (Novartis) may be effective for patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite treat